The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A meta-analysis of antiangiogenic therapy for glioblastoma (GBM).
Mustafa Khasraw
Consultant or Advisory Role - Roche
Research Funding - Merck Serono
Malaka Ameratunga
No relevant relationships to disclose
Andrew B. Lassman
Consultant or Advisory Role - AbbVie; Able Associate; Agenus; Amgen; Defined Health; Easton Associates; Genentech; GlaxoSmithKline; Kyowa Hakko Kirin; Merck Sharp & Dohme; Novartis; RadMD; Roche; Sigma-Tau; Stemline Therapeutics; Synapse; Venture Inflections
Honoraria - Merck Sharp & Dohme; Omniprex
Research Funding - AbbVie; Agenus; Boehringer Ingelheim; Celldex; Genentech; MedImmune; Northwest Biotherapeutics; Novocure; Pfizer
David M. Ashley
No relevant relationships to disclose
Helen Wheeler
Consultant or Advisory Role - Roche
Research Funding - Merck Serono
Nick Pavlakis
No relevant relationships to disclose